X
27Jul

Bio-Rad Geenius HIV 1/2 Implementation

0 Comments | | Return |

CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.

Read all about it on the Communication page by clicking this link: Communications

 

 

Related

Pooled Zika Testing and New CTS Website Functionality- November 29th Update

As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...

Read More >

Update on the Ortho Conversion

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...

Read More >

CTS Portland Implements New Laboratory Information System

On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...

Read More >

CTS Phoenix Implements New Laboratory Information System

On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...

Read More >

Reminder- Check flights and cargo hours for the 4th of July Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

Subscribe here to receive CTS updates!

Name